[go: up one dir, main page]

PE20180022A1 - Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos - Google Patents

Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos

Info

Publication number
PE20180022A1
PE20180022A1 PE2017001632A PE2017001632A PE20180022A1 PE 20180022 A1 PE20180022 A1 PE 20180022A1 PE 2017001632 A PE2017001632 A PE 2017001632A PE 2017001632 A PE2017001632 A PE 2017001632A PE 20180022 A1 PE20180022 A1 PE 20180022A1
Authority
PE
Peru
Prior art keywords
metoxy
novelty
salts
methylmethanamine
pyrrol
Prior art date
Application number
PE2017001632A
Other languages
English (en)
Inventor
Chun Ho Lee
Seung Chul Lee
Yeon Im Lee
Deok Ki Eom
Mi Ryeong Han
Eun Ji Koh
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of PE20180022A1 publication Critical patent/PE20180022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1-[1-(FENIL-SULFONIL)-4-METOXI-5-FENIL-1H-PIRROL-3-IL]-N-METILMETANAMINA DE FORMULA (1) DONDE R1, R2 Y R3 SON CADA UNO H O HALOGENO; R4 Y R5 SON CADA UNO H, HALOGENO, ALQUILO C1-4, ALCOXILO C1-4, HALOALQUILO C1-4 O HALOALCOXILO C1-4. SON COMPUESTOS PREFERIDOS: 1-(5-(2-FLUOROFENIL)-4-METOXI-1-((3-CLOROFENIL)SULFONIL)-1H-PIRROL-3-IL)-N-METILMETANAMINA; 1-(5-(2-CLOROFENIL)-4-METOXI-1-((3-METOXIFENIL)SULFONIL)-1H-PIRROL-3-IL)-N-METILMETANAMINA; ENTRE OTROS. DICHOS COMPUESTOS POSEEN ACTIVIDAD INHIBIDORA DE LA BOMBA DE PROTONES, ACTIVIDAD ERRADICADORA DE HELICOBACTER PYLORI Y ACTIVIDAD INHIBIDORA CONTRA GPCR (RECEPTOR ACOPLADO A PROTEINAS G) SIENDO UTILES EN EL TRATAMIENTO DE GASTRITIS, ESOFAGITIS POR REFLUJO O HELICOBACTER PYLORI
PE2017001632A 2015-04-27 2016-04-27 Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos PE20180022A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150058712 2015-04-27
KR1020160013588A KR101613245B1 (ko) 2015-04-27 2016-02-03 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
PE20180022A1 true PE20180022A1 (es) 2018-01-09

Family

ID=55916928

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001632A PE20180022A1 (es) 2015-04-27 2016-04-27 Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos

Country Status (29)

Country Link
US (1) US10100010B1 (es)
EP (1) EP3197867B1 (es)
JP (1) JP6244498B1 (es)
KR (2) KR101613245B1 (es)
CN (1) CN107001263B (es)
AU (1) AU2016255308B2 (es)
CA (1) CA2977750C (es)
CL (1) CL2017002571A1 (es)
CO (1) CO2017010539A2 (es)
DO (2) DOP2017000230A (es)
EC (1) ECSP17071036A (es)
ES (1) ES2703709T3 (es)
HR (1) HRP20182066T1 (es)
HU (1) HUE042449T2 (es)
MA (1) MA40887B1 (es)
MX (1) MX2017012507A (es)
MY (1) MY193257A (es)
NZ (1) NZ734896A (es)
PE (1) PE20180022A1 (es)
PH (1) PH12017501755B1 (es)
PL (1) PL3197867T3 (es)
PT (1) PT3197867T (es)
RS (1) RS58076B1 (es)
RU (1) RU2663895C1 (es)
SA (1) SA517390127B1 (es)
SG (1) SG11201706877RA (es)
SI (1) SI3197867T1 (es)
TN (1) TN2017000424A1 (es)
WO (1) WO2016175555A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017164575A1 (en) * 2016-03-25 2017-09-28 Daewoong Pharmaceutical Co.,Ltd. Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine
KR20170113040A (ko) 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102081920B1 (ko) * 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) * 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
WO2020060213A1 (ko) 2018-09-19 2020-03-26 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
WO2021125874A1 (ko) 2019-12-18 2021-06-24 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물
PH12022553498A1 (en) * 2020-06-17 2024-04-22 Ildong Pharmaceutical Co Ltd Novel acid secretion inhibitor and use thereof
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
WO2022051979A1 (zh) * 2020-09-10 2022-03-17 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
TW202241409A (zh) * 2020-12-18 2022-11-01 南韓商大熊製藥股份有限公司 包含1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之用於經口投予的新調配物
PH12023553209A1 (en) 2021-05-26 2024-02-19 Daewoong Pharmaceutical Co Ltd Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
TWI892291B (zh) * 2021-05-26 2025-08-01 南韓商大熊製藥股份有限公司 含有1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之液體醫藥組成物之醫藥容器
WO2022250469A1 (ko) 2021-05-26 2022-12-01 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 주사용 제제
KR102556500B1 (ko) * 2021-11-19 2023-07-19 하나제약 주식회사 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물
WO2023113474A1 (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
JP2024545449A (ja) * 2021-12-15 2024-12-06 デウン ファーマシューティカル カンパニー リミテッド フェックスプラザン注射剤組成物の用法用量
KR102802551B1 (ko) * 2021-12-15 2025-05-07 유노비아 주식회사 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물
US20250268862A1 (en) * 2022-04-25 2025-08-28 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
CN119365448A (zh) * 2022-05-23 2025-01-24 日东制药株式会社 一种6-甲氧基吡啶-3-基衍生物的制备方法
TW202411216A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法
CN115557876A (zh) * 2022-10-26 2023-01-03 四川国康药业有限公司 一种用于治疗消化性溃疡的3-芳环基磺酰基-1-n-杂吡咯衍生物、其制备方法和用途
KR20240127136A (ko) 2023-02-15 2024-08-22 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
WO2025174041A1 (ko) * 2024-02-13 2025-08-21 유노비아 주식회사 6-메톡시피리딘-3-일 유도체를 포함하는 위장관 질환의 치료 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511613A (ja) 2001-11-08 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患治療用アザビシクロ置換ヘテロアリール化合物
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2006023462A1 (en) 2004-08-23 2006-03-02 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
CA2579087C (en) 2004-09-03 2012-05-01 Yuhan Corporation Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
JP5173192B2 (ja) * 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
EP1799306B1 (en) 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
NZ566378A (en) * 2005-08-30 2011-03-31 Takeda Pharmaceutical 1-Heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
DE102005041246A1 (de) 2005-08-31 2007-03-08 Basf Coatings Ag Von Molybän- und Wolframverbindungen freie, Cäsiumverbindungen enthaltende, härtbare Gemische auf der Basis blockierter Polyisocyanate, Verfahren zu ihrer Herstellung und ihre Verwendung
CN102321077A (zh) 2005-12-19 2012-01-18 拉夸里亚创药株式会社 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
AU2007247231B2 (en) 2006-05-04 2012-05-31 Solvay Pharmaceuticals B.V. Muscarinic agonists to treat impulse control disorders
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
MX339805B (es) 2010-04-22 2016-06-10 Intra Cellular Therapies Inc Compuestos organicos.
WO2014075575A1 (zh) * 2012-11-19 2014-05-22 江苏豪森药业股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105120865A (zh) 2013-03-15 2015-12-02 阿卡蒂亚药品公司 蕈毒碱激动剂
ITBS20130175A1 (it) 2013-11-22 2015-05-23 Ind Saleri Italo Spa Gruppo pompa di raffreddamento regolabile con girante regolabile
WO2015134539A1 (en) 2014-03-03 2015-09-11 The Regents Of The University Of California Mcl-1 antagonists
CN104447191B (zh) 2014-10-30 2016-03-23 绵阳达高特新材料有限公司 4-溴-1,2-二氢环丁烯并[α]萘化合物及其制备方法
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途

Also Published As

Publication number Publication date
PH12017501755A1 (en) 2018-04-02
US10100010B1 (en) 2018-10-16
KR101818704B1 (ko) 2018-02-21
MA40887B1 (fr) 2019-01-31
RU2663895C1 (ru) 2018-08-13
DOP2017000230A (es) 2017-10-31
NZ734896A (en) 2019-07-26
WO2016175555A8 (en) 2017-09-08
CO2017010539A2 (es) 2018-01-31
AU2016255308B2 (en) 2017-08-31
JP6244498B1 (ja) 2017-12-06
PT3197867T (pt) 2019-01-10
EP3197867A2 (en) 2017-08-02
ES2703709T3 (es) 2019-03-12
DOP2021000213A (es) 2021-11-15
HUE042449T2 (hu) 2019-06-28
JP2017538716A (ja) 2017-12-28
HRP20182066T1 (hr) 2019-02-08
TN2017000424A1 (en) 2019-04-12
MX2017012507A (es) 2018-01-30
EP3197867B1 (en) 2018-11-14
WO2016175555A2 (en) 2016-11-03
CN107001263B (zh) 2018-10-19
CA2977750C (en) 2019-06-11
CN107001263A (zh) 2017-08-01
RS58076B1 (sr) 2019-02-28
SG11201706877RA (en) 2017-09-28
EP3197867A4 (en) 2017-09-06
SI3197867T1 (sl) 2019-02-28
WO2016175555A3 (en) 2017-02-16
SA517390127B1 (ar) 2020-11-08
CL2017002571A1 (es) 2018-03-16
ECSP17071036A (es) 2017-12-01
MA40887A (fr) 2017-08-02
AU2016255308A1 (en) 2017-05-18
PH12017501755B1 (en) 2022-11-16
KR101613245B1 (ko) 2016-04-18
CA2977750A1 (en) 2016-11-03
PL3197867T3 (pl) 2019-03-29
KR20160127646A (ko) 2016-11-04
MY193257A (en) 2022-09-28
BR112017020056A2 (pt) 2018-06-05

Similar Documents

Publication Publication Date Title
PE20180022A1 (es) Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos
PE20200604A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
MX388749B (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak.
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX391812B (es) Agonista fxr derivado de esteroides.
EA201892415A1 (ru) Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
MA40219B1 (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA201891315A1 (ru) Твердые дисперсии, содержащие стимулятор sgc
ECSP19051409A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20181015A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20170186A1 (es) Nuevos compuestos
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
EA201790570A1 (ru) Модуляторы р2х7